Altamira Therapeutics announced that Pharma Nordic will market and distribute Bentrio bentonite-based OTC nasal spray for protection against allergens in Norway as part of a deal that could potentially expand to include Sweden, Finland, and Denmark, “subject to meeting certain milestones.” Pharma Nordic will begin selling Bentrio in Norway in 2024, the company said.
Bentrio is currently available in Germany and received 510k clearance in the US in June 2022. Earlier this year, Altamira announced that a trial comparing Bentrio to saline nasal spray in patients with seasonal allergic rhinitis met its primary endpoint, and the company has just announced publication of data in the journal Clinical and Translational Allergy.
Altamira Chairman and CEO Thomas Meyer commented, “We are very pleased to collaborate with Pharma Nordic to make Bentrio also available to patients in Scandinavia. We have been impressed by Pharma Nordic’s dedication to bringing innovative products to patients in Scandinavia and the team’s rich experience and great track record in business development, medical affairs and marketing in the life science sector. We look forward to building Bentrio together with Pharma Nordic into one of the leading brands for allergic rhinitis management in Scandinavia.”
Pharma Nordic CEO Bent Andreassen said, “We’re excited about launching Bentrio, as it is a unique, preservative-free and drug-free solution that demonstrates impressive efficacy against both seasonal and perennial allergic rhinitis. These characteristics make it a highly suitable product for our Nordic customers, aligning with our region’s emphasis on safe and effective healthcare solutions.”
Read the Altamira Therapeutics press release.
